- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
- Interventions
- Ibrexafungerp
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
- Interventions
- Not listed
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
- Conditions
- Candidiasis, Vulvovaginal
- Interventions
- OCF001 Intravaginal Gel, Placebo Gel
- Drug
- Lead sponsor
- Sano Chemicals Inc
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Oteseconazole (VT-1161), Placebo
- Drug
- Lead sponsor
- Mycovia Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo
- Drug
- Lead sponsor
- Mycovia Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Encino, California • Los Angeles, California + 30 more
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- VT-1161, Placebo
- Drug
- Lead sponsor
- Viamet
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more
- Conditions
- Vulvovaginal Candidiasis
- Interventions
- NDV-3A, NDV-3, Placebo
- Biological
- Lead sponsor
- NovaDigm Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Oteseconazole (VT-1161), Placebo
- Drug
- Lead sponsor
- Mycovia Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more